KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharya, Saveri, Socinski, Mark A., Burns, Timothy F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678136/
https://www.ncbi.nlm.nih.gov/pubmed/26668062
http://dx.doi.org/10.1186/s40169-015-0075-0
_version_ 1782405400243470336
author Bhattacharya, Saveri
Socinski, Mark A.
Burns, Timothy F.
author_facet Bhattacharya, Saveri
Socinski, Mark A.
Burns, Timothy F.
author_sort Bhattacharya, Saveri
collection PubMed
description The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS-RAF-MEK-ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.
format Online
Article
Text
id pubmed-4678136
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-46781362015-12-22 KRAS mutant lung cancer: progress thus far on an elusive therapeutic target Bhattacharya, Saveri Socinski, Mark A. Burns, Timothy F. Clin Transl Med Review The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS-RAF-MEK-ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted. Springer Berlin Heidelberg 2015-12-14 /pmc/articles/PMC4678136/ /pubmed/26668062 http://dx.doi.org/10.1186/s40169-015-0075-0 Text en © Bhattacharya et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Bhattacharya, Saveri
Socinski, Mark A.
Burns, Timothy F.
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
title KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
title_full KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
title_fullStr KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
title_full_unstemmed KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
title_short KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
title_sort kras mutant lung cancer: progress thus far on an elusive therapeutic target
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678136/
https://www.ncbi.nlm.nih.gov/pubmed/26668062
http://dx.doi.org/10.1186/s40169-015-0075-0
work_keys_str_mv AT bhattacharyasaveri krasmutantlungcancerprogressthusfaronanelusivetherapeutictarget
AT socinskimarka krasmutantlungcancerprogressthusfaronanelusivetherapeutictarget
AT burnstimothyf krasmutantlungcancerprogressthusfaronanelusivetherapeutictarget

Ejemplares similares